### Dear Colleague,

Drug abuse and addiction have been inextricably linked with HIV/AIDS and hepatitis C since the beginning of these epidemics. While intravenous drug use is a well known vector for the spread of HIV/AIDS, less recognized is the role that drug abuse plays more generally in the spread of HIV by increasing the likelihood of high-risk sex with infected partners. Injection drug use and other drug-associated risky behaviors account for many of the new HIV infections, and 5 million people worldwide were newly infected in 2003. There are approximately 1 million people living with HIV infection in the United States today, out of an estimated 40 million across the globe.

HIV and HCV share common routes of transmission and risk factors. Injection drug use is a major risk factor for both infections, and an estimated 80–90 percent of HIV/HCV co-infected persons are injection drug users. Approximately 4 million Americans (1.8 percent of the U.S. population) and an estimated 200 million more around the world are infected with HCV.

HCV is one of the leading causes of chronic liver disease. Both drug abuse and co-occurring infections are associated with serious medical consequences including liver disease, a constellation of neurocognitive deficits (e.g., memory impairment, psychomotor slowing, and executive dysfunction), and other complications such as depression, anxiety, apathy, and fatigue.

This day-long symposium will address issues important to the clinicians and healthcare providers who treat drug-addicted populations. A group of clinicians and scientists (including infectious disease specialists, hepatologists, and psychiatrists) will discuss basic, epidemiological, and clinical issues of HIV/HCV including disease progression, the role of nutrition, neuropsychiatric and psychological complications, and interventions now available to clinicians and healthcare providers. Presenters will also identify research gaps and provide directions for future research.

Sincerely,

Nora D. Volkow, M.D.

Director

National Institute on Drug Abuse National Institutes of Health


#### **SPONSORED BY:**

National Institute on Drug Abuse/NIH and
American Society of Addiction Medicine

### **Symposium Organizers:**

NIDA/NIH Jag H. Khalsa, Ph.D. Frank Vocci, Ph.D. National Institute on Drug Abuse, NIH U.S. Department of Health and Human Services and

**American Society of Addiction Medicine** 



# CLINICAL APPROACHES TO HIV AND HEPATITIS C INFECTIONS IN DRUG ABUSERS

ASAM's 37th Annual Medical-Scientific Conference

Friday, May 5, 2006 10:30 a.m. — 5:30 p.m.

Sheraton San Diego Hotel and Marina San Diego, California



## Symposium Agenda

4:20-5:00

**Panel Discussion and** 

**Adjournment** 

ASAM's 37th Annual Medical-Scientific Conference Friday, May 5, 2006 San Diego, CA

### **CHAIRS:**

Jag H. Khalsa, Ph.D.
Chief
Medical Consequences Branch
National Institute on Drug Abuse
National Institutes of Health

### Frank Vocci, Ph.D.

Director
Division of Pharmacotherapies and
Medical Consequences of Drug Abuse
National Institute on Drug Abuse
National Institutes of Health

MORNING SESSION		AFTERNOON SESSION			
Clinical Approaches to HIV and Hepatitis C Infections in Drug Abusers 10:30-10:45 Welcome and Introduction Jag H. Khalsa, Ph.D. and		Medical Complications of Hepatitis C and HIV Infections  Moderator: Brian Edlin, M.D.		Infectious Diseases and Addictions: Complicated Therapies for Complicated Diseases	
Epidemiology in Drug Abuso	Frank Vocci, Pb.D. NIDA/NIH and Pathogenesis of Infections	1:00-1:20	Psychiatric/Neuropsychiatric Complications of HIV/HCV Infections in Drug Abusers Charles Hinkin, Ph.D. Professor	3:00-3:20	Jack Stapleton, M.D.  Clinical Trials of HIV/HCV Infections Ken Sherman, M.D. Professor of Medicine
Moderator: Richard Garfein, Ph.D.			University of California at Los Angeles		University of Cincinnati
10:45-11:05	HIV/HCV Infections and Drug Abuse: Update Richard Garfein, Ph.D. Associate Professor University of California at San Diego San Diego, CA	1:20-1:40	Los Angeles, CA  Managing Dual Infections in Drug Abusers Brian R. Edlin, M.D. Associate Professor Cornell University	3:20-3:40	Treatment Problems in Co-infected Drug Abusers Robert Horsburgh, M.D. Professor Boston University Boston, MA
11:05-11:25	Pathophysiology of Infections in Drug Abusers Ramesh Ganju, Ph.D. Associate Professor Harvard University	1:40-2:00	New York, NY  The Effects of HIV Infection on The Humoral Response to HCV Andrea Cox, M.D. Assistant Professor Johns Hopkins University School	3:40-4:00	Drug Interactions in HIV/HCV Co-infected Drug Abusers Jack Stapleton, M.D. Professor University of Iowa Iowa City, IA  New Medications for the Treatment of Dual Infections in Drug Abusers Ellen Tedaldi, M.D. Professor of Medicine Temple University Philadelphia, PA
11:25-11:45	Boston, MA  HCV Variants and Immunology	2:00-2:20	of Medicine Baltimore, MD	4:00-4:20	
	in Drug Abusers  James Ryan, M.D.  Associate Professor  University of California at San Francisco		Role of Nutrition in Infections in Drug Abusers Kristy Hendricks, Sc.D. Assistant Professor Tufts University		

Boston, MA

BREAK

**Panel Discussion** 

2:20-2:40

2:40-3:00

San Francisco, CA

**Panel Discussion** 

**LUNCH** 

11:45-Noon

Noon-1:00